An integrated model for the assessment of global water resources ? Part 1: Input meteorological forcing and natural hydrological cycle modules

International audienceAn integrated global water resources model was developed consisting of six modules: land surface hydrology, river routing, crop growth, reservoir operation, environmental flow requirement estimation, and anthropogenic water withdrawal. It simulates both natural and anthropogenic water flow globally (excluding Antarctica) on a daily basis at a spatial resolution of 1°×1° (longitude and latitude). The simulation period is 10 years, from 1986 to 1995. This first part of the two-feature report describes the input meteorological forcing and natural hydrological cycle modules of the integrated model, namely the land surface hydrology module and the river routing module. The input meteorological forcing was provided by the second Global Soil Wetness Project (GSWP2), an international land surface modeling project. Several reported shortcomings of the forcing component were improved. The land surface hydrology module was developed based on a bucket type model that simulates energy and water balance on land surfaces. Simulated runoff was compared and validated with observation-based global runoff data sets and observed streamflow records at 32 major river gauging stations around the world. Mean annual runoff agreed well with earlier studies at global, continental, and continental zonal mean scales, indicating the validity of the input meteorological data and land surface hydrology module. In individual basins, the mean bias was less than ±20% in 14 of the 32 river basins and less than ±50% in 24 of the basins. The performance was similar to the best available precedent studies with closure of energy and water. The timing of the peak in streamflow and the shape of monthly hydrographs were well simulated in most of the river basins when large lakes or reservoirs did not affect them. The results indicate that the input meteorological forcing component and the land surface hydrology module provide a framework with which to assess global water resources, with the potential application to investigate the subannual variability in water resources. GSWP2 participants are encouraged to re-run their model using this newly developed meteorological forcing input, which is in identical format to the original GSWP2 forcing input

Distinct and Essential Roles of Transcription Factors IRF-3 and IRF-7 in Response to Viruses for IFN-α/β Gene Induction

AbstractInduction of the interferon (IFN)-α/β gene transcription in virus-infected cells is an event central to innate immunity. Mice lacking the transcription factor IRF-3 are more vulnerable to virus infection. In embryonic fibroblasts, virus-induced IFN-α/β gene expression levels are reduced and the spectrum of the IFN-α mRNA subspecies altered. Furthermore, cells additionally defective in IRF-7 expression totally fail to induce these genes in response to infections by any of the virus types tested. In these cells, a normal profile of IFN-α/β mRNA induction can be achieved by coexpressing both IRF-3 and IRF-7. These results demonstrate the essential and distinct roles of the two factors, which together ensure the transcriptional efficiency and diversity of IFN-α/β genes for the antiviral response

Phospholipase Cbeta4 and protein kinase Calpha and/or protein kinase CbetaI are involved in the induction of long term depression in cerebellar Purkinje cells.

Activation of the type-1 metabotropic glutamate receptor (mGluR1) signaling pathway in the cerebellum involves activation of phospholipase C (PLC) and protein kinase C (PKC) for the induction of cerebellar long term depression (LTD). The PLC and PKC isoforms that are involved in LTD remain unclear, however. One previous study found no change in LTD in PKCgamma-deficient mice, thus, in the present study, we examined cerebellar LTD in PLCbeta4-deficient mice. Immunohistochemical and Western blot analyses of cerebellum from wild-type mice revealed that PLCbeta1 was expressed weakly and uniformly, PLCbeta2 was not detected, PLCbeta3 was expressed predominantly in caudal cerebellum (lobes 7-10), and PLCbeta4 was expressed uniformly throughout. In PLCbeta4-deficient mice, expression of total PLCbeta, the mGluR1-mediated Ca(2+) response, and LTD induction were greatly reduced in rostral cerebellum (lobes 1-6). Furthermore, we used immunohistochemistry to localize PKCalpha, -betaI, -betaII, and -gamma in mouse cerebellar Purkinje cells during LTD induction. Both PKCalpha and PKCbetaI were found to be translocated to the plasmamembrane under these conditions. Taken together, these results suggest that mGluR1-mediated activation of PLCbeta4 in rostral cerebellar Purkinje cells induced LTD via PKCalpha and/or PKCbetaI

SiN AlGaN カイメン ノ デンシ コウゾウ ト ゲートリーク デンリュウ ノ カンケイ

AlGaN/GaN high electron mobility transistors (HEMTs) are recently applied to high-power RF devices. However, their relatively large gate leakage currents are preventing further improvement of Applications. The large gate leakage currents strongly depend on kinds of ap assivation film. In this study, in order to clarify the correlation between passivation films and gate leakage currents, we investigated the core-level electronic structure at the interface between an AlGaN barrier layer and a passivation film by using Hard X-ray Photoemission Spectroscopy (HAXPES) at BL16XU of SPring-8. At first we fabricated AlGaN/GaN HEMTs with the three kinds of SiN passivation films deposited by different N2 flow rates and measured their gate leakage currents. The gate leakage currents increased as lower N2 flow rate conditions. Then, we found the core level spectra by HAXPES shifted according to N2 flow rate conditions. These results indicate the gate leakage currents depend on the potential height at SiN/ AlGaN interface

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

BACKGROUND Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and inter-leukin-23, was evaluated as an intravenous induction therapy in two populations with moderately to severely active Crohn’s disease. Ustekinumab was also evaluated as subcutaneous maintenance therapy. METHODS We randomly assigned patients to receive a single intravenous dose of ustekinumab (either 130 mg or approximately 6 mg per kilogram of body weight) or placebo in two induction trials. The UNITI-1 trial included 741 patients who met the criteria for primary or secondary nonresponse to tumor necrosis factor (TNF) antagonists or had unacceptable side effects. The UNITI-2 trial included 628 patients in whom conventional therapy failed or unacceptable side effects occurred. Patients who completed these induction trials then participated in IM-UNITI, in which the 397 patients who had a response to ustekinumab were randomly assigned to receive subcutaneous maintenance injections of 90 mg of ustekinumab (either every 8 weeks or every 12 weeks) or placebo. The primary end point for the induction trials was a clinical response at week 6 (defined as a decrease from baseline in the Crohn’s Disease Activity Index [CDAI] score of ≥100 points or a CDAI score <150). The primary end point for the maintenance trial was remission at week 44 (CDAI score <150). RESULTS The rates of response at week 6 among patients receiving intravenous ustekinumab at a dose of either 130 mg or approximately 6 mg per kilogram were significantly higher than the rates among patients receiving placebo (in UNITI-1, 34.3%, 33.7%, and 21.5%, respectively, with P≤0.003 for both comparisons with placebo; in UNITI-2, 51.7%, 55.5%, and 28.7%, respectively, with P<0.001 for both doses). In the groups receiving maintenance doses of ustekinumab every 8 weeks or every 12 weeks, 53.1% and 48.8%, respectively, were in remission at week 44, as compared with 35.9% of those receiving placebo (P = 0.005 and P = 0.04, respectively). Within each trial, adverse-event rates were similar among treatment groups. CONCLUSIONS Among patients with moderately to severely active Crohn’s disease, those receiving intravenous ustekinumab had a significantly higher rate of response than did those receiving placebo. Subcutaneous ustekinumab maintained remission in patients who had a clinical response to induction therapy. (Funded by Janssen Research and Development; ClinicalTrials.gov numbers, NCT01369329, NCT01369342, and NCT01369355.